A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 137,897 shares of AKBA stock, worth $474,365. This represents 0.0% of its overall portfolio holdings.

Number of Shares
137,897
Previous 126,380 9.11%
Holding current value
$474,365
Previous $235,000 12.34%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

BUY
$1.69 - $2.84 $19,463 - $32,708
11,517 Added 9.11%
137,897 $264,000
Q4 2024

Feb 14, 2025

BUY
$1.26 - $2.13 $15,412 - $26,054
12,232 Added 10.72%
126,380 $235,000
Q3 2024

Nov 14, 2024

BUY
$0.94 - $1.55 $107,299 - $176,929
114,148 New
114,148 $150,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $632M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Mirae Asset Global Etfs Holdings Ltd. Portfolio

Follow Mirae Asset Global Etfs Holdings Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Etfs Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Etfs Holdings Ltd. with notifications on news.